Discover Biotech Digital Health Pharma FDA & EMA ONCOLife Contact

Tracy Mokwe

Health Tech Content Specialist

With over 3 years of experience as a medical laboratory scientist and writer, I am passionate about translating complex scientific information into clear and accessible content. My expertise lies in medical sciences, laboratory science and research, digital health, AI, and cybersecurity in healthcare.

Latest Posts From Tracy Mokwe

New Horizons in Schizophrenia Treatment: Phase 2 Trial of ALTO-101 Targets Cognitive Dysfunction

Psychiatry

/

25 June 2024

New Horizons in Schizophrenia Treatment: Phase 2 Trial of ALTO-101 Targets Cognitive Dysfunction

FDA Approves Clinical Trials for ZW171: A Novel Bispecific Antibody for Hard-to-Treat Cancers

FDA & EMA

/

21 June 2024

FDA Approves Clinical Trials for ZW171: A Novel Bispecific Antibody for Hard-to-Treat Cancers

Beyond Visualization: The Promise of VGT-309 in Minimally Invasive Lung Cancer Surgery

ONCOLife

/

22 May 2024

Beyond Visualization: The Promise of VGT-309 in Minimally Invasive Lung Cancer Surgery

New Treatment for AA Hepatitis: Larsucosterol Earns FDA Breakthrough Designation

FDA & EMA

/

24 May 2024

New Treatment for AA Hepatitis: Larsucosterol Earns FDA Breakthrough Designation

GenFleet Receives FDA Approval for P3 Trial of GFH925 in Colorectal Cancer Treatment

FDA & EMA

/

29 April 2024

GenFleet Receives FDA Approval for P3 Trial of GFH925 in Colorectal Cancer Treatment

Roche's Blood Test for Alzheimer's Earns FDA Breakthrough Device Designation

FDA & EMA

/

18 April 2024

Roche's Blood Test for Alzheimer's Earns FDA Breakthrough Device Designation

FDA Approves Groundbreaking Gene Therapy for Children with Rare Genetic Disorder

FDA & EMA

/

20 March 2024

FDA Approves Groundbreaking Gene Therapy for Children with Rare Genetic Disorder

Pancreatic Cancer Therapy Cambritaxestat Receives FDA Orphan Drug Designation

FDA & EMA

/

9 March 2024

Pancreatic Cancer Therapy Cambritaxestat Receives FDA Orphan Drug Designation

CAR-T Therapy and Multiple Sclerosis: A New Horizon for Disease Management

Neurology

/

4 March 2024

CAR-T Therapy and Multiple Sclerosis: A New Horizon for Disease Management

Digital Therapeutics: The Promise of Virtual Reality Masks in Treating PTSD Symptoms

Digital Health

/

13 February 2024

Digital Therapeutics: The Promise of Virtual Reality Masks in Treating PTSD Symptoms

Natera's Novel Blood Test Signatera Offers New Hope for Early Lung Cancer Detection

ONCOLife

/

3 February 2024

Natera's Novel Blood Test Signatera Offers New Hope for Early Lung Cancer Detection

Rznomics' RNA-Based Therapy Receives FDA Orphan Drug Status for Liver Cancer

FDA & EMA

/

2 February 2024

Rznomics' RNA-Based Therapy Receives FDA Orphan Drug Status for Liver Cancer

Vergent's VGT-309 Shows Promise in Real-Time Visualization of Tumors During Surgery

ONCOLife

/

1 February 2024

Vergent's VGT-309 Shows Promise in Real-Time Visualization of Tumors During Surgery

FDA Grants Orphan Drug Status to NeoImmuneTech's NT-I7 for Pancreatic Cancer

FDA & EMA

/

30 January 2024

FDA Grants Orphan Drug Status to NeoImmuneTech's NT-I7 for Pancreatic Cancer

FDA Grants Breakthrough Device Designation to Amadix's Blood Test PreveCol for CRC

FDA & EMA

/

27 January 2024

FDA Grants Breakthrough Device Designation to Amadix's Blood Test PreveCol for CRC

The Global CAR T-Cell Therapy Market's Ascent: From $8.2 B in 2022 to $11.2 B by 2030

Pharma

/

26 January 2024

The Global CAR T-Cell Therapy Market's Ascent: From $8.2 B in 2022 to $11.2 B by 2030

New Treatment for Colorectal Cancer: BOLD-100 Shows Positive Results at ASCO GI 2024

ONCOLife

/

23 January 2024

New Treatment for Colorectal Cancer: BOLD-100 Shows Positive Results at ASCO GI 2024

Tarsier Pharma Secures FDA Agreement for Phase 3 Trial of Ophthalmic Solution for Uveitis

FDA & EMA

/

18 January 2024

Tarsier Pharma Secures FDA Agreement for Phase 3 Trial of Ophthalmic Solution for Uveitis

Castle's Innovative Gene Expression Tests Transform Clinical Decisions for Skin Cancer

Biotech

/

16 January 2024

Castle's Innovative Gene Expression Tests Transform Clinical Decisions for Skin Cancer

Deloitte's Survey Uncovers Optimism and Concerns in Generative AI Adoption

Opinion

/

15 January 2024

Deloitte's Survey Uncovers Optimism and Concerns in Generative AI Adoption

BioTrace: First FDA-Cleared Ultrasound Software for Liver Tumor Response Prediction

Medical Devices

/

10 January 2024

BioTrace: First FDA-Cleared Ultrasound Software for Liver Tumor Response Prediction

Milestone in Women's Health: Qvin's QPad Gains FDA Approval for Menstrual Blood Testing

FDA & EMA

/

8 January 2024

Milestone in Women's Health: Qvin's QPad Gains FDA Approval for Menstrual Blood Testing

Bloodstream Infection Treatment: Phase 3 Trial of Mino-Lok Completed

Pharma

/

3 January 2024

Bloodstream Infection Treatment: Phase 3 Trial of Mino-Lok Completed

FDA Approves Everest's Nefecon for IgA Nephropathy Treatment

FDA & EMA

/

22 December 2023

FDA Approves Everest's Nefecon for IgA Nephropathy Treatment

World's First Chronic Migraine Therapy System Successfully Implanted in Six Patients

Medical Devices

/

20 December 2023

World's First Chronic Migraine Therapy System Successfully Implanted in Six Patients

NeuExcell's AAV Gene Therapy Granted FDA Orphan Drug Designation for Glioma

FDA & EMA

/

18 December 2023

NeuExcell's AAV Gene Therapy Granted FDA Orphan Drug Designation for Glioma

Medtronic's PulseSelect PFA System Earns FDA Approval for Atrial Fibrillation Treatment

Medical Devices

/

15 December 2023

Medtronic's PulseSelect PFA System Earns FDA Approval for Atrial Fibrillation Treatment

Depixus and Daiichi Sankyo Collaborate to Accelerate RNA-targeted Drug Discovery

Pharma

/

14 December 2023

Depixus and Daiichi Sankyo Collaborate to Accelerate RNA-targeted Drug Discovery

NATALEE Trial: Novartis' Kisqali Achieves 25% Reduction in Breast Cancer Recurrence Risk

ONCOLife

/

13 December 2023

NATALEE Trial: Novartis' Kisqali Achieves 25% Reduction in Breast Cancer Recurrence Risk

Servier Unveils Tibsovo Data at ASH Meeting: Acute Myeloid Leukemia Treatment

ONCOLife

/

12 December 2023

Servier Unveils Tibsovo Data at ASH Meeting: Acute Myeloid Leukemia Treatment

A New Phase in ALS Treatment: NurOwn Enters a Crucial Stage Following FDA Meeting

FDA & EMA

/

10 December 2023

A New Phase in ALS Treatment: NurOwn Enters a Crucial Stage Following FDA Meeting

AstraZeneca and AbelZeta Jointly Co-Develop CAR-T Cancer Therapy in China

Pharma

/

9 December 2023

AstraZeneca and AbelZeta Jointly Co-Develop CAR-T Cancer Therapy in China

Merck and Acceleration Collaborate to Revolutionize Scientific Discovery with AI

Digital Health

/

7 December 2023

Merck and Acceleration Collaborate to Revolutionize Scientific Discovery with AI

FDA Grants Breakthrough Designation to J&J's TAR-200 for Bladder Cancer

FDA & EMA

/

6 December 2023

FDA Grants Breakthrough Designation to J&J's TAR-200 for Bladder Cancer

Pfizer Announces Positive Phase 2b Outcomes for Obesity Drug Candidate, Danuglipron

Clinical Trials

/

5 December 2023

Pfizer Announces Positive Phase 2b Outcomes for Obesity Drug Candidate, Danuglipron

Biohaven Presents Promising Data for new epilepsy drug BHV-7000 at AES 2023

Pharma

/

4 December 2023

Biohaven Presents Promising Data for new epilepsy drug BHV-7000 at AES 2023

Astellas' Fezolinetant Offers New Hope for Menopause VMS Without Hormones

Pharma

/

2 December 2023

Astellas' Fezolinetant Offers New Hope for Menopause VMS Without Hormones

Everest's Etrasimod Shows Promising Results in P3 Trial for Ulcerative Colitis

Clinical Trials

/

1 December 2023

Everest's Etrasimod Shows Promising Results in P3 Trial for Ulcerative Colitis

BD Launches Vascular Access Ultrasound System to Enhance Clinician Efficiency

Medical Devices

/

30 November 2023

BD Launches Vascular Access Ultrasound System to Enhance Clinician Efficiency

New Acoustic AI Model Achieves 83% Accuracy in Detecting Depression

Digital Health

/

29 November 2023

New Acoustic AI Model Achieves 83% Accuracy in Detecting Depression

FDA Clears BrainSpec's AI-Powered MRS Platform for Brain Disease Diagnosis

FDA & EMA

/

28 November 2023

FDA Clears BrainSpec's AI-Powered MRS Platform for Brain Disease Diagnosis

China’s First KRAS Inhibitor GFH925 Receives Priority Review for Lung Cancer

ONCOLife

/

27 November 2023

China’s First KRAS Inhibitor GFH925 Receives Priority Review for Lung Cancer